Cornerstone Therapeutics Inc. Stock Downgraded (CRTX)

NEW YORK (TheStreet) -- Cornerstone Therapeutics (Nasdaq:CRTX) has been downgraded by TheStreet Ratings from hold to sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.

• ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Highlights from the ratings report include:

• The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Pharmaceuticals industry. The net income has significantly decreased by 204.8% when compared to the same quarter one year ago, falling from $1.74 million to -$1.83 million.
• The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Pharmaceuticals industry and the overall market, CORNERSTONE THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
• Net operating cash flow has significantly decreased to -$2.71 million or 107.69% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
• Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 28.91%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 200.00% compared to the year-earlier quarter. Turning toward the future, the fact that the stock has come down in price over the past year should not necessarily be interpreted as a negative; it could be one of the factors that may help make the stock attractive down the road. Right now, however, we believe that it is too soon to buy.
• CORNERSTONE THERAPEUTICS INC has exprienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. However, the consensus estimate suggests that this trend should reverse in the coming year. During the past fiscal year, CORNERSTONE THERAPEUTICS INC swung to a loss, reporting -$0.03 versus $0.23 in the prior year. This year, the market expects an improvement in earnings ($0.11 versus -$0.03).

Cornerstone Therapeutics Inc., a specialty pharmaceutical company, engages in the acquisition, development, and commercialization of prescription pharmaceutical drugs for the hospital, niche respiratory, and related specialty markets. Cornerstone has a market cap of $170.4 million and is part of the health care sector and drugs industry. Shares are up 15.9% year to date as of the close of trading on Monday.

You can view the full Cornerstone Ratings Report or get investment ideas from our investment research center.

-- Written by a member of TheStreet Ratings Staff

TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

 

For more information on Cornerstone Therapeutics Inc. click any of the following:

• Cornerstone Therapeutics Inc. Stock Price

• Cornerstone Therapeutics Inc. Analyst Ratings

• Cornerstone Therapeutics Inc. Key Stats & Profile

• Cornerstone Therapeutics Inc. Earnings

• Cornerstone Therapeutics Inc. Ratio Comparison

• Cornerstone Therapeutics Inc. Growth Rates

• Cornerstone Therapeutics Inc. Balance Sheet

• Cornerstone Therapeutics Inc. Cash Flow

• Cornerstone Therapeutics Inc. Income Statement